Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,686 total articles
Kraft Heinz (KHC) trades like a beaten-down staple: a $27.6B market cap, ~7% yield, solid free cash flow and single-digit EV/EBITDA. This is an income-oriented long with upside if margins stabilize. Trade plan provided for a measured, conviction-weighted position over a 180 trading-day horizon.
Micron (MU) has sold off on headlines about Chinese DRAM competition and high-profile shorts, but the company's fundamentals - record DRAM/NAND revenues, FCF of ~$59B, low leverage and a P/E near 12 - argue this is a sentiment-driven correction rather than a structural break. We reaffirm Buy and outline an actionable entry at $900 with a $1,200 tar…
Constellation Energy’s string of long-term nuclear PPAs with hyperscalers gives it near-term revenue visibility and contracting optionality that Vistra lacks. Vistra’s $4.2B DOE conditional loan is positive, but its heavier leverage, tighter liquidity metrics, and longer execution timeline mean it’s more exposed to downside while markets re-price w…
Marvell plunged roughly 10% into a washout that creates a defined risk/reward for disciplined buyers. The company just pushed out aggressive revenue targets for AI-era data centers and retains solid margins and free cash flow. This trade idea lays out an exact entry at $235.00, a conservative stop at $205.00, and a 180-day target of $320.00, with c…
Carrefour (CRRFY) offers a contrarian, high-risk long setup around $3.78. The stock trades at a modest valuation (market cap ~$13.9B, P/E ~14.5, P/B ~1.0) and carries a 4.18% yield, but the turnaround depends on Germany/Europe execution, margin stabilization, and execution on loyalty/digital initiatives. This trade is tactical: entry $3.78, stop $3…
Sky Harbour builds and leases premium private-aviation hangars and home-base solutions for business aircraft. At a current price near $9.07 and an enterprise value of roughly $753M, the company looks like a high-risk, high-reward real estate developer: strong niche pricing power and a wealthy customer base offset by negative free cash flow, elevate…
Rocket Lab (RKLB) has been hit hard in recent sessions, trading down from its May highs and showing oversold momentum. The company still posts strong top-line traction (Q2 revenue of $235M; $2.36B backlog) and has shareholder approval for an $8B Iridium acquisition that could transform it into a vertically integrated satellite operator. This trade …
Oscar Health has moved from growth-at-all-costs to a business showing durable membership gains, improving medical loss ratios and expanding operating earnings. With guidance raised for 2026 operating earnings and revenue visibility near $19B, the stock looks set for a rerating into 2027 if the company sustains margin progress and churn stabilizes. …
Nebius (NBIS) has been one of 2025-26's fastest-growing neocloud names, but a heavy selloff and a string of macro and industry headlines make the stock vulnerable in the coming weeks. With a market cap near $46.9B, negative technical momentum, and tenuous credit/valuation optics in a higher-rate regime, this trade idea recommends a tactical short w…
IonQ's stock cratered after an equity-and-warrant financing announced at $40 per share, creating a rare entry for a speculative long. Fundamentals and sector catalysts (DARPA progress, recent M&A and partnerships) justify a play on recovering sentiment, but the company's cash burn, heavy dilution and negative profitability make this a high-risk tra…
uniQure’s stock has been punished for weaker-than-expected 48-month durability data for AMT-130 in Huntington’s disease and ensuing legal noise. The company still has a BLA filed based on stronger 36-month results, a $225M equity cushion from the June offering, and a market cap near $1.5B. With the shares deeply oversold (RSI ~19) and heavy short i…
Disney has reshaped its cost base, restored free cash flow and lowered leverage. With a market cap near $192B, FCF of roughly $8.3B, and a P/E in the low-20s, the company is positioned to sustain content investment, sports rights and parks upgrades that make it hard for rivals to erode market share. We lay out an actionable long with entry, stop an…
Ardagh Metal Packaging (AMBP) is a global beverage can maker trading at $4.456 with a market cap of $2.66B and a chunky dividend yield (~9.24%). The business benefits from long-term demand for aluminum cans, but the capital structure and negative book value leave the stock vulnerable. We present a mid-term short trade (45 trading days) with explici…
ICF International (ICFI) is a mid-cap consulting and technology services firm that has built a credible beachhead in utility program technology while retaining steady government and commercial consulting revenue. With a market cap near $1.6B, an EV/EBITDA of ~9.9, and a free cash flow conversion of roughly $199M, the stock looks positioned for a mi…
Credo (CRDO) pulled back sharply from recent highs but still carries accelerating revenue, strong free cash flow and several near-term catalysts. Valuation is rich and execution risk is real, but the current $170 area offers an attractive asymmetric trade: disciplined entry at $170, stop at $150 and a $260 target for a position held into product ra…
MasTec (MTZ) trades near its recent low yet carries exposure to communications and clean-energy infrastructure projects that should benefit from sustained data-center and grid modernization spending. At roughly $15B market cap with P/S ~1.0 and EV/EBITDA ~14x, the stock looks attractively priced for a swing trade while the company’s FCF and ROE sup…
Sandisk (SNDK) has been sold off hard into oversold technicals despite industry tailwinds from AI infrastructure and tight NAND supply. Fundamentals are robust: free cash flow ~$11.5B, EPS north of $79 and ROE above 70%. This trade idea outlines a disciplined long with an entry at $1,320, a primary target of $2,000 and a stop at $1,150 over a 180-t…
Scribe Therapeutics is a clinical-stage developer of in vivo CRISPR-based genetic medicines with a compact market cap of roughly $397M and a platform-led upside profile. Technicals and short-interest dynamics make it a tradable long with asymmetric upside if upcoming platform and clinical catalysts validate delivery and efficacy. This idea lays out…
Pinterest blends high-margin, asset-light economics with improving monetization and AI-driven content relevance. At roughly $12.3B market cap and $21.76 per share, the risk/reward tilts in favor of a tactical long on a mid-term horizon. This trade targets regained multiple expansion as engagement and ad yield pick up, while keeping a disciplined st…
Jazz Pharmaceuticals is shifting from a sleep-and-epilepsy story to a more diversified oncology + CNS commercial franchise. Positive OS data and a recent label expansion for Ziihera, plus the Actio acquisition and strong free cash flow, give the stock a catalyst-driven upside while valuation remains reasonable at ~14.5x earnings. This trade targets…
Arrowhead is being re‑priced by clinical momentum: a positive ARO-MAPT readout appears to validate CNS delivery and expands the addressable opportunity for its RNAi platform. The stock is trading on attractive technicals (RSI ~27) with elevated short interest, and the company still carries a large market cap of roughly $8.25B despite negative earni…
Zevra (ZVRA) combines a clean balance sheet and meaningful free cash flow with an FDA-approved rare-disease drug that appears conservatively priced versus market comparables. The stock trades at an enterprise value below what you'd expect for a company with positive cash flow, an approved product and a $150M voucher sale behind it. This trade targe…
Western Digital has the product mix and revenue momentum to be a clear AI infrastructure beneficiary, yet recent selling has pushed the stock to an attractive entry. We lay out an actionable trade with precise entry, stop and target, plus the catalysts and risks that will determine whether WDC re-rates toward a more normal growth multiple.
New Oriental’s pivot away from K-12 tutoring into adult education, test prep, and livestream commerce is producing real margin recovery and revenue growth. Recent operational beats, stronger guidance, and large institutional buys argue for a tactically long swing trade into a likely Q1 beat. Risk-managed entry at $57.50 with a $68 target balances u…
AeroVironment (AVAV) is trading near $120 with a market cap around $6.1B, a cheap P/S relative to its growth runway, and a record funded backlog. This trade idea takes a constructive long stance: enter on weakness, limit downside with a tight stop, and target a meaningful re-rating as contracts convert to revenue and margins recover.
